Triques K, Coste J, Perret J L, Segarra C, Mpoudi E, Reynes J, Delaporte E, Butcher A, Dreyer K, Herman S, Spadoro J, Peeters M
Laboratoire Retrovirus, ORSTOM, Montpellier, France.
J Clin Microbiol. 1999 Jan;37(1):110-6. doi: 10.1128/JCM.37.1.110-116.1999.
Three versions of a commercial human immunodeficiency virus (HIV) type 1 (HIV-1) load test (the AMPLICOR HIV-1 MONITOR Test versions 1. 0, 1.0+, and 1.5; Roche Diagnostics, Branchburg, N.J.) were evaluated for their ability to detect and quantify HIV-1 RNA of different genetic subtypes. Plasma samples from 96 patients infected with various subtypes of HIV-1 (55 patients infected with subtype A, 9 with subtype B, 21 with subtype C, 2 with subtype D, 7 with subtype E, and 2 with subtype G) and cultured virus from 29 HIV-1 reference strains (3 of subtype A, 6 of subtype B, 5 of subtype C, 3 of subtype D, 8 of subtype E, 3 of subtype F, and 1 of subtype G) were tested. Detection of subtypes A and E was significantly improved with versions 1.0+ and 1.5 compared to that with version 1. 0, whereas detection of subtypes B, C, D, and G was equivalent with the three versions. Versions 1.0, 1.0+, and 1.5 detected 65, 98, and 100% of the subtype A-infected samples from patients, respectively, and 71, 100, and 100% of the subtype E-infected samples from patients, respectively. Version 1.5 yielded a significant increase in viral load for samples infected with subtypes A and E (greater than 1 log10 HIV RNA copies/ml). For samples infected with subtype B, C, and D and tested with version 1.5, only a slight increase in viral load was observed (<0.5 log10). We also evaluated a prototype automated version of the test that uses the same PCR primers as version 1.5. The results with the prototype automated test were highly correlated with those of the version 1.5 test for all subtypes, but were lower overall. The AMPLICOR HIV-1 MONITOR Test, version 1.5, yielded accurate measurement of the HIV load for all HIV-1 subtypes tested, which should allow the test to be used to assess disease prognosis and response to antiretroviral treatment in patients infected with a group M HIV-1 subtype.
对商用1型人类免疫缺陷病毒（HIV-1）载量检测的三个版本（AMPLICOR HIV-1 MONITOR检测版本1.0、1.0+和1.5；罗氏诊断公司，新泽西州布兰奇堡）检测和定量不同基因亚型HIV-1 RNA的能力进行了评估。检测了96例感染不同亚型HIV-1患者的血浆样本（55例感染A亚型、9例感染B亚型、21例感染C亚型、2例感染D亚型、7例感染E亚型、2例感染G亚型）以及29株HIV-1参考毒株的培养病毒（3株A亚型、6株B亚型、5株C亚型、3株D亚型、8株E亚型、3株F亚型、1株G亚型）。与版本1.0相比，版本1.0+和1.5对A和E亚型的检测有显著改善，而对B、C、D和G亚型的检测在三个版本中相当。版本1.0、1.0+和1.5分别检测出患者中感染A亚型样本的65%、98%和100%，以及感染E亚型样本的71%、100%和100%。版本1.5使感染A和E亚型的样本病毒载量显著增加（大于1 log10 HIV RNA拷贝/ml）。对于感染B、C和D亚型并使用版本1.5检测的样本，仅观察到病毒载量略有增加（<0.5 log10）。我们还评估了使用与版本1.5相同PCR引物的该检测的原型自动化版本。原型自动化检测的结果与版本1.5检测对所有亚型的结果高度相关，但总体较低。AMPLICOR HIV-1 MONITOR检测版本1.5对所有检测的HIV-1亚型的HIV载量都能进行准确测量，这应使该检测可用于评估感染M组HIV-1亚型患者的疾病预后和对抗逆转录病毒治疗的反应。
